Possible role for chlorpheniramine in the treatment of L-DOPA induced dyskinesia in Parkinson's disease

被引：1
作者：
Karamanakos, Petros N.
Pappas, Periklis
Marselos, Marios
机构：
[1] Kuopio Univ Hosp, Dept Neurosurg, FI-70211 Kuopio, Finland
[2] Univ Ioannina, Sch Med, Dept Pharmacol, Ioannina 45110, Greece
来源：
PHARMACY WORLD & SCIENCE | 2008年 / 30卷 / 01期
关键词：
chlorpheniramine; L-DOPA; Parkinson's disease; pharmacotherapy;
D O I：
10.1007/s11096-007-9138-7
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：1 / 2
页数：2
相关论文
共 5 条
[1]   Influence of initial use of serotonergic antidepressants on antiparkinsonian drug use in levodopa-using patients [J].
Arbouw, Maurits E. L. ;
Movig, Kris L. L. ;
Neef, Cees ;
Guchelaar, Henk-Jan ;
Egberts, Toine C. G. .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2007, 63 (02) :181-187
[2]   Activation of 5-HT1A but not 5-HT1B receptors attenuates an increase in extracellular dopamine derived from exogenously administered L-DOPA in the striatum with nigrostriatal denervation [J].
Kannari, K ;
Yamato, H ;
Shen, H ;
Tomiyama, M ;
Suda, T ;
Matsunaga, M .
JOURNAL OF NEUROCHEMISTRY, 2001, 76 (05) :1346-1353
[3]   Involvement of the brain serotonergic system in the locomotor stimulant effects of chlorpheniramine in Wistar rats:: implication of postsynaptic 5-HT1A receptors [J].
Karamanakos, PN ;
Pappas, P ;
Marselos, M .
BEHAVIOURAL BRAIN RESEARCH, 2004, 148 (1-2) :199-208
[4]   Multicenter, open-label, trial of sarizotan in Parkinson disease patients with levodopa-induced dyskinesias (the SPLENDID study) [J].
Olanow, CW ;
Damier, P ;
Goetz, CG ;
Mueller, T ;
Nutt, J ;
Rascol, O ;
Serbanescu, A ;
Deckers, F ;
Russ, H .
CLINICAL NEUROPHARMACOLOGY, 2004, 27 (02) :58-62
[5]   A serotonin 5-HT1A receptor agonist prevents behavioral sensitization to L-DOPA in a rodent model of Parkinson's disease [J].
Tomiyama, M ;
Kimura, T ;
Maeda, T ;
Kannari, K ;
Matsunaga, M ;
Baba, M .
NEUROSCIENCE RESEARCH, 2005, 52 (02) :185-194
1